Promising results for new tuberculosis therapy

Bagchi, Sanjit
January 2008
CMAJ: Canadian Medical Association Journal;1/1/2008, Vol. 178 Issue 1, p19
Academic Journal
The article talks about the possibility of having a shorter duration treatment for tuberculosis as shown in preliminary findings from a clinical trial. The findings show that new combination therapy which includes Moxifloxacin, an antibiotic, has the capability to cut the needed time to sure drug-susceptible tuberculosis to period of four to six months. The mentioned drug is presently in its advanced stage of clinical trials and may possible be on the market by the year 2012 to help nations like India which struggles due to high incidence of tuberculosis.


Related Articles

  • Once-weekly treatment as effective as daily treatment in TB continuation phase.  // Infectious Disease News;Apr2013, Vol. 26 Issue 4, p19 

    The article discusses the RIFAQUIN study conducted by Dr. Amina Jindani and colleagues which found that once-weekly administration of rifapentine and moxifloxacin for tuberculosis treatment is effective as the standard daily treatment.

  • Antibiotic-resistant Ocular Surface Flora After IVT Injection.  // Review of Ophthalmology;Jul2013, Vol. 20 Issue 7, p71 

    The article offers information on the side-effect of routine use of topical moxifloxacin after intravitreal injection that can lead to an increased antibiotic resistance in ocular surface flora.

  • Moxifloxacin-based regimens for tuberculosis.  // Africa Health;Nov2014, Vol. 37 Issue 1, p51 

    The article discusses the study which aims to determine if the replacement of isoniazid or ethambutol with moxifloxacin is effective in improving rates of adherence and adverse effects on tuberculosis.

  • Moxifloxacin resistance in the F15/LAM4/KZN extensively drug-resistant strain of Mycobacterium tuberculosis. Dookie, Navisha; Sturm, A. Willem; Moodley, Prashini // Infection & Drug Resistance;2014, Vol. 7, p223 

    Objectives: Moxifloxacin (MXF) has been advocated for the treatment of extensively drugresistant (XDR) tuberculosis despite resistance to older-generation fluoroquinolones. We investigated the relationship between the minimum inhibitory concentration (MIC) of MXF and mutations in the gyrA and...

  • Evaluation of a Rifapentine-Containing Regimen for Intensive Phase Treatment of Pulmonary TB.  // MD Conference Express;Aug2011, p8 

    The article reports on research which was conducted by Susan E. Dorman of Johns Hopkins University in Baltimore, Maryland in an effort to investigate the effectiveness of using a rifapentine-containing or rifampin-containing regimen in the intensive phase treatment of pulmonary tuberculosis....

  • Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI). Chuchalin, Alexander; Zakharova, Maryna; Dokic, Dejan; Tokić, Mahir; Marschall, Hans-Peter; Petri, Thomas // BMC Pulmonary Medicine;2013, Vol. 13 Issue 1, p1 

    Background: Acute exacerbations of chronic bronchitis (AECB), including chronic obstructive pulmonary disease (AECOPD), represent a substantial patient burden. Few data exist on outpatient antibiotic management for AECB/ AECOPD in Eastern/South Eastern Europe, in particular on the use of...

  • Hezeyanî Parazitoz Tedavisinde Ketiyapin. Ünsalver, Barış Önen; Uygunoğlu, Uğur; Ertan, Turan; Eker, Engin // Yeni Symposium;2009, Vol. 47 Issue 1, p34 

    Quetiapine Therapy In Delusions Of Parasitosis Delusions of parasitosis (DP) is a rare psychiatric disorder in which the patient is preoccupied with a fixed, false belief of being infested by insects, worms or other living organisms, without additional thought disorder. Although, DP may occur at...

  • Moxifloxacin.  // Reactions Weekly;2/27/2010, Issue 1290, p34 

    The article describes the case of five patients who acquired uveitis-like syndrome while undergoing treatment with oral moxifloxacin.

  • La recherche clinique en cancérologie thoracique: place et rôle de l’Intergroupe francophone de cancérologie thoracique (IFCT). Teixeira, L.; Trédaniel, J.; Zalcman, G.; Morin, F.; Milleron, B. // Oncologie;Jun2009, Vol. 11 Issue 6, p343 

    The French Intergroup of Thoracic Oncology (IFCT) aims to develop clinical research in all fields of thoracic oncology, and has recently implemented innovative phase III trials. The purpose of this article is to briefly describe active clinical trials as well as completed studies.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics